The report “Patient Derived Xenograft/PDX Models Market
by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological,
Respiratory), Application (Pre-Clinical Drug Development &
Biomarker Analysis), End User (Pharma & Biotech, CRO) – Global
Forecast to 2022″, The PDX models market is expected to reach
USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at
a CAGR of 16.7%. The key factors driving the growth of this market
include the growing demand for personalized medicine, continuous support
for cancer research from the public as well as private sectors, and
growth in the number of R&D activities in the pharmaceutical
industry. The growing use of humanized PDX models is posing a lucrative
opportunity in this market.
Browse 44 Market Data Tables and 34 Figures spread through 148 Pages and in-depth TOC on “Patient
Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor
Type (Gastrointestinal, Gynecological, Respiratory), Application
(Pre-Clinical Drug Development & Biomarker Analysis), End User
(Pharma & Biotech, CRO) – Global Forecast to 2022”
Early buyers will receive 10% customization on reports.
By tumor type, the gastrointestinal tumor models segment accounted for the largest share of the market in 2017
On the basis of tumor type, the PDX models market has
been segmented into gastrointestinal tumor models, gynecological tumor
models, respiratory tumor models, urological tumor models, hematological
tumor models, and other tumor models such as head & neck tumors,
sarcoma, and melanoma. In 2017, the gastrointestinal tumors segment is
expected to account for the largest share of the global PDX models
market. The respiratory tumors segment, on the other hand, is expected
to be the fastest-growing segment during the forecast period. Growth in
this segment is mainly driven by the increasing focus of market players
on generating lung cancer PDX models, which could lead to a breakthrough
in lung cancer treatment as lung cancer is the leading cause of
cancer-related deaths across the globe.
Download PDF Brochure : http://www.marketsandmarkets.com/pdfdownload.asp?id=121598251
By application, the preclinical drug development and basic cancer research held the largest market share in 2017
Based on application, the PDX models market is
further segmented into the preclinical drug development & basic
cancer research and biomarker analysis. In 2017, the preclinical drug
development and basic cancer research segment is expected to account for
the largest share of the global PDX models market. The large share of
this segment can be mainly attributed to the increasing number of
research activities in the field of oncology drug research.
North America dominated the market in 2017
North America accounted for the largest share of the
PDx models market in 2017, followed by Europe. The large share of the
North American PDX models market can be attributed to the growth in
biomedical research in the US, rising preclinical activities by CROs and
pharmaceutical companies, and growing stem cell research in Canada.
However, the Asia Pacific market is projected to grow at the highest
CAGR during the forecast period, owing to strong research expenditure
and the well-structured CRO industry in China, growth in biomedical
& medical research in Japan, rising pharmaceutical R&D
expenditure in India, and rising translational and biomedical research
in Singapore.
The various players in the PDX models market include
Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology,
Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles
River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH
(Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France),
Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs
(US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research
on 30,000 high growth niche opportunities/threats which will impact 70%
to 80% of worldwide companies’ revenues. Currently servicing 5000
customers worldwide including 80% of global Fortune 1000 companies as
clients. Almost 75,000 top officers across eight industries worldwide
approach MarketsandMarkets™ for their painpoints around revenues
decisions.
Our 850 fulltime analyst and SMEs at
MarketsandMarkets™ are tracking global high growth markets following the
“Growth Engagement Model – GEM”. The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify
most important customers, write “Attack, avoid and defend” strategies,
identify sources of incremental revenues for both the company and its
competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies
this year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research
ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence
and market research platform, “RT” connects over 200,000 markets and
entire value chains for deeper understanding of the unmet insights along
with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment